An Engineered Extracellular Vesicle With Enhanced Tumor and Lymph Nodes Targeting as siRNA Delivery System for Robust Tumor Immunotherapy.
MedComm
Wang Y, Zhang R, Zhou X, Tang L, Hu D, Zhang Y, Yang Y, Zhou B, Yang L.
Publication Overview
Key findings, Countstar context, and access to the original paper.
2026
Cancer Research
Immunology
No items found.
Key Finding
In vivo experiments showed that DP-EVs/siPD-L1 significantly inhibited tumor growth and prolonged survival in tumor-bearing mice. Collectively, the findings demonstrate that DP-EVs/siPD-L1 functions as an effective therapeutic vaccine, which synergistically activates antitumor immunity and reverses immunosuppression through targeted PD-L1 blockade.
Countstar Connection
The study obtained migrated- or invaded-cell counts from the study's cell samples using Countstar (model not specified) during the study's migration assessment.
